| HOOKIPA Pharma is a biopharmaceutical company developing a class of immunotherapeutics based on its proprietary arenavirus platform that is designed to target and amplify a T cell and immune response to disease. Co. is building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and antigens. Co.'s lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus 16-positive cancers in a Phase 1/2 clinical trial. Co.'s non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is a potential compound in a Phase 2 clinical trial for kidney transplant patients. We show 14 historical shares outstanding datapoints in our HOOK shares outstanding history coverage, used to compute HOOK market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HOOK market cap history over the course of time is important for investors
interested in comparing HOOK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HOOK versus a peer is one thing; comparing
HOOK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HOOK can fluctuate over the course of history.
With this page we aim to empower investors researching HOOK by allowing them to research the HOOK market cap history.